Katerzia (Amlodipine Benzoate) Patent Expiration, LOE Window & CMS Spending

Katerzia (Amlodipine Benzoate) by Azurity: FDA Orange Book LOE 2039-04-11, 19 AB generics, $11.6M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN211340 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-04-11
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors19
2024 CMS Total Public Spend$11.6M
2024 Medicare Part D Spend$1.5M
2024 Medicaid Spend$10.1M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.0% 2-yr change)